Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Branded DTC Campaign Launches In 50 Publications

Executive Summary

Searle/Pfizer's first branded direct-to-consumer ad campaign for the COX-2 inhibitor Celebrex will run in approximately 50 publications after its Sept. 8 launch.

You may also be interested in...



Senate Hearings On IoM Medical Errors Report Planned For Early 2000

Senate Labor/HHS Appropriations Subcommittee Chairman Specter (R-Penn.) is planning a hearing to discuss recommendations outlined in a Nov. 29 Institute of Medicine report on medical errors and patient safety.

Senate Hearings On IoM Medical Errors Report Planned For Early 2000

Senate Labor/HHS Appropriations Subcommittee Chairman Specter (R-Penn.) is planning a hearing to discuss recommendations outlined in a Nov. 29 Institute of Medicine report on medical errors and patient safety.

Searle/Pfizer Celebrex

Celecoxib NDA for treatment of familial adenomatous polyposis will receive six-month priority review; new indication for the COX-2 inhibitor was submitted as early as the last week in June

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel